Evidence map›Paper›PMID 31843980›Full record

ArticleCancer research2020

Mass Spectrometry Imaging Enables Discrimination of Renal Oncocytoma from Renal Cell Cancer Subtypes and Normal Kidney Tissues.

Jialing Zhang, Shirley Q Li, John Q Lin, Wendong Yu, Livia S Eberlin

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Spatial pharmacology using mass spectrometry imaging.Trends in pharmacological sciences · 2024
    Review
  12. Article
  13. Promise of spatially resolved omics for tumor research.Journal of pharmaceutical analysis · 2023
    Review
  14. Article
  15. Article
  16. Article
  17. Metabolic signature ofFrontiers in veterinary science · 2023
    Article
  18. Review
  19. Emerging Computational Methods in Mass Spectrometry Imaging.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jialing ZhangDepartment of Chemistry, The University of Texas at Austin, Austin, Texas.
Shirley Q LiDepartment of Chemistry, The University of Texas at Austin, Austin, Texas.
John Q LinDepartment of Chemistry, The University of Texas at Austin, Austin, Texas.ORCID 0000-0001-5888-3107
Wendong YuDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, Texas. liviase@utexas.edu wendong.yu@bcm.edu.
Livia S EberlinDepartment of Chemistry, The University of Texas at Austin, Austin, Texas. liviase@utexas.edu wendong.yu@bcm.edu.
The University of Texas at Austin · USBaylor College of Medicine · US

Funding

Mass Spectrometry Imaging for Clinical Diagnosis and Prognosis of Human CancersR00CA190783 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI SCHIAVINATO EBERLIN, LIVIA · 2016 to 2018
$677k
NCI NIH HHS R00 CA190783
6 · The paper itself

Abstract

Precise diagnosis and subtyping of kidney tumors are imperative to optimize and personalize treatment decision for patients. Patients with the most common benign renal tumor, renal oncocytomas, may be overtreated with surgical resection because of limited preoperative diagnostic methods that can accurately identify the benign condition with certainty. In this study, desorption electrospray ionization (DESI)-mass spectrometry (MS) imaging was applied to study the metabolic and lipid profiles of various types of renal tissues, including normal kidney, renal oncocytoma, and renal cell carcinomas (RCC). A total of 73,992 mass spectra from 71 patient samples were obtained and used to build predictive models using the least absolute shrinkage and selection operator (Lasso). Overall accuracies of 99.47% per pixel and 100% per patient for prediction of the three tissue types were achieved. In particular, renal oncocytoma and chromophobe RCC, which present the most significant morphologic overlap and are sometimes indistinguishable using histology alone, were also investigated and the predictive models built yielded 100% accuracy in discriminating these tumor types. Discrimination of three subtypes of RCC was also achieved on the basis of DESI-MS imaging data. Importantly, several small metabolites and lipids species were identified as characteristic of individual tissue types and chemically characterized using tandem MS and high mass accuracy measurements. Collectively, our study shows that the metabolic data acquired by DESI-MS imaging in conjunction with statistical modeling allows discrimination of renal tumors and thus has the potential to be used in the clinical setting to improve treatment of patients with kidney tumor. SIGNIFICANCE: Metabolic data acquired by mass spectrometry imaging in conjunction with statistical modeling allows discrimination of renal tumors and has the potential to be used in the clinic to improve treatment of patients.

Indexed as

Adenoma, OxyphilicBiomarkers, TumorCarcinoma, Renal CellDiagnosis, DifferentialHumansKidneyKidney NeoplasmsLipid MetabolismSpectrometry, Mass, Electrospray IonizationBiomarkers, Tumor

Identifiers

PMID31843980
PMCPMC7024663
OpenAlexW2994619165

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.